Background: Acute kidney injury (AKI) in the neonatal intensive care setting is multifactorial and is associated with significant morbidity and mortality. This study evaluates the utility of novel urinary biomarkers to predict the development and/or severity AKI in preterm infants. Methods: We performed a case-control study on a prospective cohort of preterm infants (<32 wk), to compare seven urine biomarkers between 25 infants with AKI and 20 infants without AKI. results: Infants with AKI had significantly higher neutrophil gelatinase-associated lipocalin (NGAL) (median, control (CTRL) vs. AKI; 0.598 vs. 4.24 µg/ml; P < 0.0001). In contrast, urinary epidermal growth factor (EGF) levels were significantly lower in infants who developed AKI compared to controls (median, CTRL vs. AKI; 0.016 vs. 0.006 µg/ml; P < 0.001). The area under the curve (AUC) for NGAL for prediction of stage I AKI on the day prior to AKI diagnosis (day-1) was 0.91, and for the prediction of stage II/III, AKI was 0.92. Similarly, urine EGF was a predictor of renal injury on day -1 (AUC: 0.97 for stage I and 0.86 for stage II/III AKI). conclusion: Urinary biomarkers may be useful to predict AKI development prior to changes in serum creatinine (SCr) in preterm infants.
i n recent decades, several advances in neonatal medicine has enhanced survival for preterm infants, most notably pulmonary surfactant and improved ventilation strategies. However, in most cases, the incidence of major morbidities has changed very little, especially for extremely premature infants (1, 2) . Acute kidney injury (AKI), indicated by a rise in serum creatinine (SCr) occurs in approximately 12-18% of preterm neonates (3) . Premature infants typically have immature renal structure and function at birth, are often exposed to nephrotoxic medications and are at high risk of AKI in the perinatal period. Very recent studies have demonstrated that the extrauterine environment is not optimal for kidney development, an effect which could be exaggerated in those with AKI (4) . It has also been recognized that small changes in neonatal kidney function in this vulnerable population are associated with short-term consequences (fluid overload, increased length of stay, and death) (5-7). The role that AKI plays in the development of chronic kidney disease (CKD) in this population is still unknown. Few case reports document that CKD occurs in infants who had AKI; however, these studies are small singlecenter retrospective reports (8) .
Current methodology identifying renal dysfunction is based upon serum creatinine and urine output (UOP). The shortcomings of SCr and UOP to define AKI are well documented including: (i) a lag between initial renal injury and creatinine rise, (ii) inability to differentiate specific site of renal injury, (iii) increasing unreliability of creatinine measurement with increasing degree of renal injury due to tubular secretion of creatinine, and (iv) Renal supportive therapy, when required, removes creatinine making prognostication difficult (9) . In the neonatal population, use of SCr to diagnose AKI is even more complex since initial neonatal creatinine reflects maternal values, which decrease over time and the estimated creatinine clearance (eCCL) changes as growth and renal development occur. The lack of reliable biomarkers of early structural kidney injury results in an undesirable delay in the clinical diagnosis. Early diagnosis of AKI in preterm infants is extremely important. Therefore, identifying earlier biomarkers of AKI is needed in this vulnerable patient population.
While investigators have begun to focus on AKI in the Adult and Pediatric Intensive Care Units, there is a paucity of data in the area of Neonatal AKI, in which the population is heterogeneous at varying gestational ages and AKI etiology is often multifactorial (10, 11) . Abitbol et al. (12) showed that serum cystatin C level is a superior biomarker to serum Cr in the assessment of GFR in a cross-sectional observational cohort of premature infants. The urine represents a rich, noninvasive source of potential biomarkers. This is particularly relevant in the neonatal population where blood-sparing studies are paramount to standard clinical care. To determine whether there is an association between candidate urinary biomarkers and AKI in this vulnerable population, we studied seven previously described urinary biomarkers: albumin,
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Articles β2-microglobulin (β2MG), cystatin C (Cys C), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), and uromodulin (UMOD) (13, 14) . Our aim was to determine whether urinary biomarkers concentrations increase before SCr elevation, and to evaluate the sensitivity and specificity of these biomarkers to predict the clinical course of AKI.
RESULTS

Baseline Demographics and Biomarkers
In the present study, 20 infants who never sustained AKI served as control (CTRL) and 25 infants who developed AKI based on the KDIGO classification served as cases. The average day of life in infants who developed AKI was 4 (range 2-7 d of life). Table 1 describes the maternal characteristics, infants' demographics, and clinical variables between those with and without AKI. No statistically significant differences in maternal demographic variables were seen between the infants with AKI and those without AKI, although no mothers of infants without AKI had chorioamnionitis, compared to 3 of 25 mothers (12%) of infants with AKI (P = 0.32). Infants with AKI had lower birth weight (mean ± SD; 752.2 ± 176.6 vs. 884.1 ± 156.6 g; P = 0.02), and lower Apgar score at 1 and 5 min than those without AKI. Otherwise, no major differences in clinical variables were detected between the two groups.
Additionally, we investigated the levels of urinary biomarkers in the control group across various gestational ages. As shown in Figure 1 , there was no statistically significant difference between urinary biomarkers studied, across different gestational ages. Figure 2 shows the differences of biomarkers values in infants with AKI and those without AKI, these biomarkers were analyzed on the day the injury initially occurred (day 0). We did not detect any statistically significant differences between control and AKI groups in the urinary levels of Albumin ( Figure 2a ) and β2MG ( Figure 2b ) (P = NS). Infants with AKI had significantly higher urinary Cys C levels ( Figure 2c ) (median CTRL vs. AKI; 0.98 vs. 6.09 µg/ml; P < 0.001), and higher NGAL (Figure 2e ) (median, CTRL vs. AKI; 0.598 vs. 4.24 µg/ml; P < 0.0001). In contrast, urinary EGF levels ( Figure 2d ) were significantly lower in infants who developed AKI compared to controls (median, CTRL vs. AKI; 0.016 vs. 0.006 µg/ml; P < 0.001).
Biomarkers Differences
Biomarkers as Early Predictors of AKI
Further, we investigated the urinary levels of selected biomarkers on the day prior to AKI diagnosis (day -1). Urinary Albumin and β2MG levels did not differ on day -1 vs. day 0. Urinary levels of Cys C, EGF, NGAL, OPN, and UMOD were at the same level as day 0 levels on day -1, these levels were significantly different from day matched control (no-AKI) group. Figure 3 demonstrates urine biomarkers levels for infants with AKI on the day they developed the renal injury (day 0) as well as the day before (day -1), and those without AKI. Table 2 shows the fold change of these biomarkers based on the values in day -1 compared to the control group. Preterm infants with lower birth weight may possibly have higher baseline values of some urinary AKI biomarkers (12) . Therefore, we incorporated birth weight into predictive models to control for this potential confounder. The area under the curve (AUC) for EGF, and NGAL for prediction of stage I AKI on day-1 was 0.97 and 0.91 respectively (Figure 4) , and for the prediction of stage II/III AKI was 0.86 and 0.92 respectively. The combination of EGF and NGAL was not significantly different in prediction of stage I AKI (AUC: 0.93) compared to EGF alone. However, the combined model using the two biomarkers improved the ability to predict stage II/III AKI compared to the models using NGAL or EGF alone (AUC: 0.95).
DISCUSSION
In this case-control study of AKI in preterm infants, we found that urinary biomarkers were associated with AKI, defined Urine NGAL has been recently reported to be a useful early AKI marker that predicted development of severe AKI in a heterogeneous group of pediatric patients admitted to the PICU with unknown timing of kidney injury (15) . A multicenter pooled analysis of prospective studies shows that NGAL can predict mortality even in the absence of diagnostic increases in serum creatinine (16) . A recent pilot study showed that higher urinary NGAL concentrations were associated with the documentation of stage I AKI, but it failed to predict its development 1-2 d earlier in preterm infants (17) . On the contrary, we found urine NGAL to be a good early marker of AKI development prior to serum creatinine rise in this cohort of Articles preterm infants. The present study provides additional support for assessing urine NGAL as a biomarker of AKI in neonates in a large multicenter trial. EGF is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. EGFR activation is required for renal regeneration and functional recovery after AKI. Smith et al. (18) demonstrated that EGF signaling pathway is activated in a mouse model of sepsis-induced AKI. Chen et al. (19) reported lower urine EGF levels in infants with severe perinatal asphyxia compared with controls, suggesting that EGF may play a role in the repair of acute renal injury after asphyxia. We controlled for birth weight as a potential confounder in evaluating the association between urine biomarkers and AKI to ensure that the detected changes in these biomarkers are not simply a reflection of prematurity (20) . Askenazi et al. (21) demonstrated that urinary biomarkers can predict AKI and mortality in very-low-birth-weight infants independent of gestational age and birth weight. This study could not however determine whether these biomarkers can detect AKI before changes in SCr occur; our findings are promising and consistent with earlier literature. We could not assess the impact of postnatal age on urinary biomarkers. Saeidi et al. (22) showed that postnatal age affects urine biomarkers measured in the first 4 d of life in preterm infants without AKI. The nested casecontrol study design was not intended to assess the incidence of AKI; it has the advantage of cost and effort reduction with relatively minor loss in statistical efficiency compared with the full-cohort approach (23) . The limitations of this study are the small number and the inability to correlate between biomarkers and clinical outcomes such as duration of mechanical ventilation or mortality. However, strength of this study is the daily urine collection that allowed us to evaluate the utility of these biomarkers in the early prediction of AKI and its evaluation of seven candidate biomarkers. We found no significant difference between urinary biomarkers studied, across different gestational ages in this small cohort. Another limitation is that serum creatinine-based gold standard definition of AKI is likely not 100% accurate in detecting AKI in neonates, as it reflects function, rather than injury. Therefore, some control infants might have had actual kidney injury, and some infants with elevated SCr might not have had kidney damage. Our emphasis is on the potential use of changes in urine biomarkers patterns as a diagnostic tool to monitor kidney function in this vulnerable population. Future studies in larger cohorts of premature infants that involve daily urine collection to evaluate these biomarkers against hard clinical endpoints will control for these limitations and allow determining which biomarkers can best predict AKI at earlier time points.
Our findings provide new insights into the potential role of these urine biomarkers in the early prediction of AKI in this vulnerable population. Validation of these novel biomarkers with respect to preclinical and clinical use, sensitivity, and specificity will provide additional tools in the early detection of kidney injury. We are currently conducting a prospective study to develop a baseline normative renal biomarkers data set for preterm infants. In conclusion, urine biomarkers can be used as noninvasive predictors of evolving neonatal renal injury in preterm infants. Early identification of AKI prior to changes in serum creatinine allows the application of renoprotective approaches such as fluid administration management and adjustment of nephrotoxic medications in the early stages of AKI. Additionally, earlier detection of AKI might enable more rapid conventional interventions or introduction of novel therapies to prevent or effectively treat such otherwise undetected AKI.
METHODS
Study Design and Patient Selection
We conducted a prospective case-control observational study to determine the ability of seven urinary biomarkers to predict AKI prior to SCr. Using prospective data collection; infants who had AKI were identified and then controls were selected from the same cohort. The study protocol and consent forms were approved by the University of Kentucky, College of Medicine Human Subjects Institutional Review Board. Preterm infants (<32 wk) admitted to the regional quaternary care neonatal intensive care unit of Kentucky Children's Hospital, were enrolled after obtaining parental consent. Infants with major congenital anomalies and those who did not survive to 48 h of life were excluded. Urine was collected once daily for the first 7 d of life by placing cotton balls at the perineum. Urine was extracted, centrifuged for 10 min to remove any cotton fibers or cellular elements, and then the supernatant was aliquoted equally into cryovials and frozen at −80 °C until sample evaluation.
The outcome of interest is the development of AKI. Neonatal AKI was defined according to the modified KDIGO (Kidney Disease | Improving Global Outcomes) classification described by Jetton et al., (10) each SCr is compared to the lowest previous SCr value. Day 0 was defined as the day on which the infant first met criteria for AKI, urine samples collected 24 h prior to day 0 (day -1) were compared with control samples to evaluate the predictive value of different urinary biomarkers.
Laboratory Analysis
SCr values were obtained prospectively as part of standard patient care from the day of admission up to 14 d of life. Serum creatinine was measured using Jaffe method traceable to isotope dilution mass spectrometry. Biomarkers analysis was performed using Meso Scale Discovery Human Kidney Injury Panel-5 Prototype 7-Plex Assay Kit (Meso Scale Discovery, Gaithersburg, MD). Reproducibility of standard duplicates was obtained with an average signal confidence of variability of 6.5%. The Human Kidney Injury Panel-5 (7-Plex assay) has picogram per milliliter (pg/ml) sensitivity and covers a broad concentration range, from low pg/ml up to 200,000 pg/ml. All the biomarkers levels were normalized to urinary creatinine levels. Final biomarkers values were expressed in micrograms per milliliter.
Statistical Analysis
Descriptive statistical analysis was performed to determine differences between groups. The Shapiro-Wilk test and the normal probability plot were used to test for normality of data. Normally distributed continuous variables were compared using Fisher exact test. Non-normal distributed continuous variables were analyzed using the Mann-Whitney U-test for two groups and Kruskal-Wallis test for multiple groups. Multiple logistic regression analysis was performed, with birth weight and AKI forced into the model, to control for birth weight as a potential confounder. For the regression analysis, biomarkers were converted to natural log to achieve normal distribution. The predictive accuracy of urine biomarkers for identifying AKI was evaluated by constructing multivariate receiver operating characteristics curves. A combination model was evaluated to examine how a combination of the two biomarkers (NGAL and EGF) could improve the ability to predict AKI. For all descriptive analysis, statistical significance was defined as an α value of 0.05.
